Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response

Mireia Uribe‐Herranz, Stavros Rafail, Silvia Beghi, Luis Gil‐de‐Gómez, Ioannis I. Verginadis, Kyle Bittinger, Sergei Pustylnikov, Stefano Pierini, Renzo Perales‐Linares, Ian A. Blair,

Journal of Clinical Investigation · 2019 · 300 citations · 49 references

DOIFull text

Open access

Concepts

Abstract

Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitumor CD8+ T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-γ. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications.

References

49